The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Schroeder Theodore R since 2009.
This trader's CIK number is 1378690.
At the time of last reporting, Schroeder Theodore R was the Chief Executive Officer of Nabriva Therapeutics Plc. (stock ticker symbol NBRV).
Also see all insider trading activities at Nabriva Therapeutics Plc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2011 | CADX | 16,000 | $119,632 | 0 | $0 | 20,000 | $0 |
| 2010 | CADX | 0 | $0 | 180,000 | $1,519,255 | 0 | $0 |
| 2009 | CADX | 0 | $0 | 20,000 | $214,380 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | NBRV | 150,000 | $113,798 | 0 | $0 | 0 | $0 |
| 2019 | NBRV | 50,000 | $89,500 | 0 | $0 | 0 | $0 |
1. Cadence Pharmaceuticals Inc (CADX)
2. Nabriva Therapeutics Plc (NBRV)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2011-11-02 | CADX | Option Ex | 20,000 | .00 | 0 |
| 2011-05-17 | CADX | Buy | 16,000 | 7.48 | 119,632 |
| 2010-10-01 | CADX | Sale | 9,297 | 8.35 | 77,667 |
| 2010-09-30 | CADX | Sale | 40,703 | 8.35 | 339,707 |
| 2010-07-01 | CADX | Sale | 8,979 | 6.95 | 62,404 |
| 2010-06-30 | CADX | Sale | 41,021 | 7.00 | 287,270 |
| 2010-04-01 | CADX | Sale | 21,997 | 9.03 | 198,632 |
| 2010-03-31 | CADX | Sale | 28,003 | 9.30 | 260,343 |
| 2010-01-04 | CADX | Sale | 10,343 | 9.80 | 101,361 |
| 2009-12-31 | CADX | Sale | 19,657 | 9.76 | 191,871 |
| 2009-10-16 | CADX | Sale | 20,000 | 10.72 | 214,380 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-12-28 | NBRV | Buy | 100,000 | .57 | 57,299 |
| 2021-09-14 | NBRV | Buy | 50,000 | 1.13 | 56,499 |
| 2019-08-27 | NBRV | Buy | 50,000 | 1.79 | 89,500 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Schroeder Theodore R (Chief Executive Officer of Nabriva Therapeutics Plc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.